Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | EYA3 | Q99504 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19732866 | 0.99 | PTPN1 (0.52) | PTPN1EYA3LMNAHTTCYP2C9 | |
| SCHEMBL2536315 | 0.85 | CYP3A4 (0.48) | PTPN1LMNAHTTCYP2C9ALDH1A1 | |
| SCHEMBL18407426 | 0.82 | PPARG (0.47) | PTPN1EYA3CYP2C9TTRPPARG | |
| SCHEMBL18407427 | 0.82 | EYA3 (0.50) | PTPN1EYA3CYP2C9TTRPPARG | |
| SCHEMBL18407419 | 0.82 | CYP2C9 (0.58) | PTPN1EYA3CYP2C9TTR | |
| SCHEMBL18407429 | 0.81 | EYA3 (0.49) | PTPN1EYA3CYP2C9PPARGALDH1A1 | |
| SCHEMBL19732865 | 0.81 | PTPN1 (0.51) | PTPN1EYA3LMNAHTTTTR | |
| SCHEMBL18222929 | 0.80 | CYP2C9 (0.47) | PTPN1EYA3CYP2C9PPARGALDH1A1 | |
| SCHEMBL4613473 | 0.80 | PPARG (0.60) | PTPN1EYA3LMNACYP2C9PPARG | |
| SCHEMBL27345511 | 0.79 | PTPN1 (0.52) | PTPN1EYA3CYP2C9TTRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022165-A1 | PQSR MODULATORS | HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH (DE) | 2017-01-26 | — | — | US | disclosed |
| US-8372866-B2 | 2-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related pain | ROTTAPHARM S.P.A. (IT) | 2013-02-12 | — | — | US | disclosed |
| EP-2268628-B1 | 2-ARYL AND 2 -HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM SPA (IT) | 2012-05-16 | — | — | EP | disclosed |
| US-20110003861-A1 | 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | ROTTAPHARM S.P.A. (IT) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003861-A1 | 2-ARYL AND 2-HETEROARYL 4H-1-BENZOPYRAN-4-ONE-6-AMIDINO DERIVATIVES, NEW PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF ARTHRITIS, CANCER AND RELATED PAIN | NAT1, AADAC, OPRL1 | PTPN1 3252/4885EYA3 4607/4885LMNA 4430/4885 |
| US-20170022165-A1 | PQSR MODULATORS | QARS1, SRPRA, MRPS35 | PTPN1 648/4885EYA3 3012/4885LMNA 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.